Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Xanodyne Pharmaceuticals revenue
Xanodyne Pharmaceuticals's revenue is $18.8 million.
What is Xanodyne Pharmaceuticals's revenue?
- Xanodyne Pharmaceuticals has 100 employees, and the revenue per employee ratio is $188,000.
- Xanodyne Pharmaceuticals peak revenue was $18.8M in 2024.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Xanodyne Pharmaceuticals financing
Xanodyne Pharmaceuticals received early financing of $5.1M on 2003-07-25.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $5.1M | 07/2003 |
| Series Unknown | $20M | 06/2004 |
| Series A | $170M | 07/2005 |
| Series A | $25M | 07/2007 |
| Series Unknown | $87.8M | 10/2009 |
Xanodyne Pharmaceuticals investors
| Investors | Security type |
|---|---|
| HealthCare Ventures | Series Unknown |
| Essex Woodlands Healthcare Partners | Series Unknown |
| MPM Capital | Series A |
| HealthCare Ventures | Series A |
| Apax Partners | Series A |
| Blue Chip Venture Company | Series A |
| HealthCare Ventures | Series A |
| MPM Capital | Series A |
| Essex Woodlands Healthcare Partners | Series A |
| Apax Partners | Series A |
| Aisling Capital | Series A |
| Blue Chip Venture Company | Series Unknown |
| Silver Point Capital, L.P. | Series Unknown |
| Union Spring Pharmaceuticals | Series Unknown |
| MPM Capital | Series Unknown |
| HealthCare Ventures | Series Unknown |
| Perseus-Soros Biopharmaceutical Fund | Series Unknown |
| Longitude Capital | Series Unknown |
| Essex Woodlands Healthcare Partners | Series Unknown |
| AIG Investments | Series Unknown |
| Aisling Capital | Series Unknown |
Xanodyne Pharmaceuticals competitors
Xanodyne Pharmaceuticals's top competitor, AstraZeneca, earned an annual revenue of $25.9B.
Xanodyne Pharmaceuticals's smallest competitor is Wraser Pharmaceutical with revenue of $4.3M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Santarus | $70,584 | $218.0M | 290 | - |
| Pharmacia | $76,833 | $130.0M | 350 | - |
| Somaxon Pharmaceuticals | $67,928 | $16.2M | 50 | - |
| Daiichi Sankyo | $82,543 | $9.0B | 15,348 | 44 |
| UCB | $67,621 | $5.7B | 7,600 | 105 |
| Organon | $73,941 | $6.4B | 158 | 137 |
| AstraZeneca | $112,988 | $25.9B | 76,100 | 419 |
| Watson Pharmaceuticals | $60,556 | $8.8M | 86 | - |
| Brad Pharm | $65,801 | $145.0M | 300 | - |
| Takeda Pharmaceuticals U.S.A., Inc. | $85,837 | $12.1B | 30,481 | 1,301 |
Xanodyne Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Xanodyne Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Xanodyne Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Xanodyne Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Xanodyne Pharmaceuticals. The data presented on this page does not represent the view of Xanodyne Pharmaceuticals and its employees or that of Zippia.
Xanodyne Pharmaceuticals may also be known as or be related to XANODYNE PHARMACEUTICALS INC and Xanodyne Pharmaceuticals.